Mechanisms coupling thrombin to metastasis and tumorigenesis

Thrombosis Research

Volumn 164, Issue , 2018, Pages S29-S33

  Remiker, Allison S ^a   Palumbo, Joseph S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Hemostatic factors; Metastasis; Thrombin; Tumorigenesis

Indexed keywords

CYTOKINE; FIBRINOGEN; INTEGRIN; THROMBIN; THROMBOPLASTIN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CAUSAL ATTRIBUTION; CELL ADHESION; COLITIS; COLON CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; HEMOSTASIS; HUMAN; INFLAMMATORY CELL; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION; CARCINOGENESIS; IMMUNOLOGY;

CARCINOGENESIS; HUMANS; NEOPLASM METASTASIS; THROMBIN;

EID: 85046028649     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.12.020     Document Type: Article

References (79)

1. Khalil, J., Bensaid, B., Elkacemi, H., Afif, M., Bensaid, Y., Kebdani, T., Benjaafar, N., Venous thromboembolism in cancer patients: an underestimated major health problem. World J. Surg. Oncol., 13, 2015, 204.
2. Wun, T., White, R.H., Epidemiology of cancer-related venous thromboembolism. Best Pract. Res. Clin. Haematol. 22:1 (2009), 9–23.
3. Key, N.S., Khorana, A.A., Mackman, N., McCarty, O.J., White, G.C., Francis, C.W., McCrae, K.R., Palumbo, J.S., Raskob, G.E., Chan, A.T., Sood, A.K., Thrombosis in cancer: research priorities identified by a National Cancer Institute/National Heart, Lung, and Blood Institute strategic working group. Cancer Res. 76:13 (2016), 3671–3675.
4. Shaib, W., Deng, Y., Zilterman, D., Lundberg, B., Saif, M.W., Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res. 30:10 (2010), 4261–4264.
5. Zacharski, L.R., Prandoni, P., Monreal, M., Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 10:1 (2005), 72–79.
6. van Doormaal, F.F., Buller, H.R., Heparin and survival in cancer patients. Hematol. Oncol. Clin. North Am. 24:4 (2010), 777–784 (ix-x).
7. Falanga, A., Marchetti, M., Heparin in tumor progression and metastatic dissemination. Semin. Thromb. Hemost. 33:7 (2007), 688–694.
8. Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin. Adv. Hematol. Oncol. H&O 1:11 (2003), 673–678.
9. Falanga, A., Thrombophilia in cancer. Semin. Thromb. Hemost. 31:1 (2005), 104–110.
10. Zhang, N., Lou, W., Ji, F., Qiu, L., Tsang, B.K., Di, W., Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. J. Cancer Res. Clin. Oncol. 142:8 (2016), 1807–1816.
11. Haaland, G.S., Falk, R.S., Straume, O., Lorens, J.B., Association of Warfarin use with Lower Overall Cancer Incidence among Patients Older than 50 years. JAMA Intern. Med. 117:12 (2017), 1774–1780.
12. Palumbo, J.S., Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin. Thromb. Hemost. 34:2 (2008), 154–160.
13. Gil-Bernabe, A.M., Lucotti, S., Muschel, R.J., Coagulation and metastasis: what does the experimental literature tell us?. Br. J. Haematol. 162:4 (2013), 433–441.
14. Schaffner, F., Yokota, N., Ruf, W., Tissue factor proangiogenic signaling in cancer progression. Thromb. Res. 129:Suppl. 1 (2012), S127–31.
15. van den Berg, Y.W., Osanto, S., Reitsma, P.H., Versteeg, H.H., The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119:4 (2012), 924–932.
16. Palumbo, J.S., Talmage, K.E., Massari, J.V., La Jeunesse, C.M., Flick, M.J., Kombrinck, K.W., Hu, Z., Barney, K.A., Degen, J.L., Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood, 19, 2007, 19.
17. Ruf, W., Tissue factor and cancer. Thromb. Res. 130:Suppl. 1 (2012), S84–7.
18. Kocaturk, B., Versteeg, H.H., Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill. J. Thromb. Haemostasis: JTH 11:Suppl. 1 (2013), 285–293.
19. Versteeg, H.H., Schaffner, F., Kerver, M., Petersen, H.H., Ahamed, J., Felding-Habermann, B., Takada, Y., Mueller, B.M., Ruf, W., Inhibition of tissue factor signaling suppresses tumor growth. Blood 111:1 (2008), 190–199.
20. Wojtukiewicz, M.Z., Hempel, D., Sierko, E., Tucker, S.C., Honn, K.V., Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis. Cancer Metastasis Rev. 35:2 (2016), 213–233.
21. Horowitz, N.A., Blevins, E.A., Miller, W.M., Perry, A.R., Talmage, K.E., Mullins, E.S., Flick, M.J., Queiroz, K.C., Shi, K., Spek, C.A., Conway, E.M., Monia, B.P., Weiler, H., Degen, J.L., Palumbo, J.S., Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood 118:10 (2011), 2889–2895 (Epub 2011 Jul 25).
22. Schenone, M., Furie, B.C., Furie, B., The blood coagulation cascade. Curr. Opin. Hematol. 11:4 (2004), 272–277.
23. Nesheim, M., Wang, W., Boffa, M., Nagashima, M., Morser, J., Bajzar, L., Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb. Haemost. 78:1 (1997), 386–391.
24. Connolly, A.J., Ishihara, H., Kahn, M.L., Farese, R.V. Jr., Coughlin, S.R., Role of the thrombin receptor in development and evidence for a second receptor. Nature 381:6582 (1996), 516–519.
25. Kahn, M.L., Nakanishi-Matsui, M., Shapiro, M.J., Ishihara, H., Coughlin, S.R., Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103:6 (1999), 879–887.
26. Kahn, M.L., Zheng, Y.W., Huang, W., Bigornia, V., Zeng, D., Moff, S., Farese, R.V. Jr., Tam, C., Coughlin, S.R., A dual thrombin receptor system for platelet activation. Nature 394:6694 (1998), 690–694.
27. Sambrano, G.R., Coughlin, S.R., The carboxyl tail of protease-activated receptor-1 is required for chemotaxis. Correlation of signal termination and directional migration. J. Biol. Chem. 274:29 (1999), 20178–20184.
28. Trejo, J., Connolly, A.J., Coughlin, S.R., The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J. Biol. Chem. 271:35 (1996), 21536–21541.
29. Palumbo, J.S., Talmage, K.E., Massari, J.V., La Jeunesse, C.M., Flick, M.J., Kombrinck, K.W., Jirouskova, M., Degen, J.L., Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:1 (2005), 178–185 (Epub 2004 Sep 14).
30. Kopp, H.G., Placke, T., Salih, H.R., Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69:19 (2009), 7775–7783.
31. Placke, T., Kopp, H.G., Salih, H.R., Modulation of natural killer cell anti-tumor reactivity by platelets. J. Innate Immun. 3:4 (2011), 374–382.
32. Nieswandt, B., Hafner, M., Echtenacher, B., Mannel, D.N., Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59:6 (1999), 1295–1300.
33. Labelle, M., Begum, S., Hynes, R.O., Platelets guide the formation of early metastatic niches. Proc. Natl. Acad. Sci. U. S. A. 111:30 (2014), E3053–61.
34. Labelle, M., Begum, S., Hynes, R.O., Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:5 (2011), 576–590.
35. Labelle, M., Hynes, R.O., The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2:12 (2012), 1091–1099.
36. Chiang, S.P., Cabrera, R.M., Segall, J.E., Tumor cell intravasation. Am. J. Phys. Cell Phys. 311:1 (2016), C1–c14.
37. Schick, P.K., Wojenski, C.M., He, X., Walker, J., Marcinkiewicz, C., Niewiarowski, S., Integrins involved in the adhesion of megakaryocytes to fibronectin and fibrinogen. Blood 92:8 (1998), 2650–2656.
38. Ugarova, T.P., Solovjov, D.A., Zhang, L., Loukinov, D.I., Yee, V.C., Medved, L.V., Plow, E.F., Identification of a novel recognition sequence for integrin alphaM beta2 within the gamma-chain of fibrinogen. J. Biol. Chem. 273:35 (1998), 22519–22527.
39. Smiley, S.T., King, J.A., Hancock, W.W., Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 167:5 (2001), 2887–2894.
40. Suehiro, K., Gailit, J., Plow, E.F., Fibrinogen is a ligand for integrin alpha5beta1 on endothelial cells. J. Biol. Chem. 272:8 (1997), 5360–5366.
41. Flick, M.J., Du, X., Degen, J.L., Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp. Biol. Med. 229:11 (2004), 1105–1110.
42. Katagiri, Y., Hiroyama, T., Akamatsu, N., Suzuki, H., Yamazaki, H., Tanoue, K., Involvement of alpha v beta 3 integrin in mediating fibrin gel retraction. J. Biol. Chem. 270:4 (1995), 1785–1790.
43. Bach, T.L., Barsigian, C., Yaen, C.H., Martinez, J., Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J. Biol. Chem. 273:46 (1998), 30719–30728.
44. Languino, L.R., Duperray, A., Joganic, K.J., Fornaro, M., Thornton, G.B., Altieri, D.C., Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc. Natl. Acad. Sci. U. S. A. 92:5 (1995), 1505–1509.
45. Flick, M.J., Du, X., Witte, D.P., Jirouskova, M., Soloviev, D.A., Busuttil, S.J., Plow, E.F., Degen, J.L., Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J. Clin. Invest. 113:11 (2004), 1596–1606.
46. Kopec, A.K., Abrahams, S.R., Thornton, S., Palumbo, J.S., Mullins, E.S., Divanovic, S., Weiler, H., Owens, A.P. 3rd, Mackman, N., Goss, A., van Ryn, J., Luyendyk, J.P., Flick, M.J., Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J. Clin. Invest. 127:8 (2017), 3152–3166.
47. Palumbo, J.S., Barney, K.A., Blevins, E.A., Shaw, M.A., Mishra, A., Flick, M.J., Kombrinck, K.W., Talmage, K.E., Souri, M., Ichinose, A., Degen, J.L., Factor, X.I.I.I., Transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J. Thromb. Haemost. 6:5 (2008), 812–819 (Epub 2008 Feb 25).
48. Palumbo, J.S., Potter, J.M., Kaplan, L.S., Talmage, K., Jackson, D.G., Degen, J.L., Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 62:23 (2002), 6966–6972.
49. DeFeo, K., Hayes, C., Chernick, M., Ryn, J.V., Gilmour, S.K., Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol. Ther. 10:10 (2010), 1001–1008.
50. Hu, L., Ibrahim, S., Liu, C., Skaar, J., Pagano, M., Karpatkin, S., Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res. 69:8 (2009), 3374–3381.
51. Hu, L., Lee, M., Campbell, W., Perez-Soler, R., Karpatkin, S., Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104:9 (2004), 2746–2751.
52. Nieman, M.T., LaRusch, G., Fang, C., Zhou, Y., Schmaier, A.H., Oral thrombostatin FM19 inhibits prostate cancer. Thromb. Haemost. 104:5 (2010), 1044–1048.
53. Schulze, E.B., Hedley, B.D., Goodale, D., Postenka, C.O., Al-Katib, W., Tuck, A.B., Chambers, A.F., Allan, A.L., The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res. Treat. 112:2 (2008), 243–254.
54. Steinbrecher, K.A., Horowitz, N.A., Blevins, E.A., Barney, K.A., Shaw, M.A., Harmel-Laws, E., Finkelman, F.D., Flick, M.J., Pinkerton, M.D., Talmage, K.E., Kombrinck, K.W., Witte, D.P., Palumbo, J.S., Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res. 70:7 (2010), 2634–2643.
55. Turpin, B., Miller, W., Rosenfeldt, L., Kombrinck, K., Flick, M.J., Steinbrecher, K.A., Harmel-Laws, E., Mullins, E.S., Shaw, M., Witte, D.P., Revenko, A., Monia, B., Palumbo, J.S., Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res. 74:11 (2014), 3020–3030.
56. Adams, G.N., Rosenfeldt, L., Frederick, M., Miller, W., Waltz, D., Kombrinck, K., McElhinney, K.E., Flick, M.J., Monia, B.P., Revenko, A.S., Palumbo, J.S., Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1, and fibrinogen. Cancer Res. 75:19 (2015), 4235–4243.
57. Magnus, N., D'Asti, E., Meehan, B., Garnier, D., Rak, J., Oncogenes and the coagulation system–forces that modulate dormant and aggressive states in cancer. Thromb. Res. 133:Suppl. 2 (2014), S1–9.
58. Milsom, C., Magnus, N., Meehan, B., Al-Nedawi, K., Garnier, D., Rak, J., Tissue factor and cancer stem cells: is there a linkage?. Arterioscler. Thromb. Vasc. Biol. 29:12 (2009), 2005–2014, 10.1161/ATVBAHA.108.177444 (Epub 2009 Jul 23).
59. Yu, J.L., May, L., Lhotak, V., Shahrzad, S., Shirasawa, S., Weitz, J.I., Coomber, B.L., Mackman, N., Rak, J.W., Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105:4 (2005), 1734–1741.
60. Vossen, C.Y., Hoffmeister, M., Chang-Claude, J.C., Rosendaal, F.R., Brenner, H., Clotting factor gene polymorphisms and colorectal cancer risk. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29:13 (2011), 1722–1727.
61. Mullins, E.S., Kombrinck, K.W., Talmage, K.E., Shaw, M.A., Witte, D.P., Ullman, J.M., Degen, S.J., Sun, W., Flick, M.J., Degen, J.L., Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood 113:3 (2009), 696–704 (Epub 2008 Oct 16).
62. Sun, W.Y., Witte, D.P., Degen, J.L., Colbert, M.C., Burkart, M.C., Holmback, K., Xiao, Q., Bugge, T.H., Degen, S.J., Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc. Natl. Acad. Sci. U. S. A. 95:13 (1998), 7597–7602.
63. Aleman, M.M., Byrnes, J.R., Wang, J.G., Tran, R., Lam, W.A., Di Paola, J., Mackman, N., Degen, J.L., Flick, M.J., Wolberg, A.S., Factor XIII activity mediates red blood cell retention in venous thrombi. J. Clin. Invest. 124:8 (2014), 3590–3600.
64. Byrnes, J.R., Wilson, C., Boutelle, A.M., Brandner, C.B., Flick, M.J., Philippou, H., Wolberg, A.S., The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues gamma390-396 and the FXIII-B subunits. Blood 128:15 (2016), 1969–1978.
65. Andersson, C., Kvist, P.H., McElhinney, K., Baylis, R., Gram, L.K., Pelzer, H., Lauritzen, B., Holm, T.L., Hogan, S., Wu, D., Turpin, B., Miller, W., Palumbo, J.S., Factor XIII transglutaminase supports the resolution of mucosal damage in experimental colitis. PLoS One, 10(6), 2015, e0128113.
66. Johnson, I.T., Lund, E.K., Review article: nutrition, obesity and colorectal cancer. Aliment. Pharmacol. Ther. 26:2 (2007), 161–181.
67. Rhodes, J.M., Campbell, B.J., Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol. Med. 8:1 (2002), 10–16.
68. Terzic, J., Grivennikov, S., Karin, E., Karin, M., Inflammation and colon cancer. Gastroenterology 138:6 (2010), 2101–2114 (e5).
69. Clevers, H., At the crossroads of inflammation and cancer. Cell 118:6 (2004), 671–674.
70. Grizzi, F., Bianchi, P., Malesci, A., Laghi, L., Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol: WJG 19:2 (2013), 174–184.
71. Park, J.H., McMillan, D.C., Horgan, P.G., Roxburgh, C.S., The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat. Rev. 40:1 (2014), 68–77.
72. Cuzick, J., Otto, F., Baron, J.A., Brown, P.H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H.J., Thun, M., Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10:5 (2009), 501–507.
73. Lochhead, P., Chan, A.T., Statins and colorectal cancer. Clin. Gastroenterol. Hepatol.:Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 11:2 (2013), 109–118 (quiz e13-4).
74. Baltgalvis, K.A., Berger, F.G., Pena, M.M., Davis, J.M., Muga, S.J., Carson, J.A., Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Phys. Regul. Integr. Comp. Phys. 294:2 (2008), R393–401.
75. McClellan, J.L., Davis, J.M., Steiner, J.L., Day, S.D., Steck, S.E., Carmichael, M.D., Murphy, E.A., Intestinal inflammatory cytokine response in relation to tumorigenesis in the Apc(min/+) mouse. Cytokine 57:1 (2012), 113–119.
76. Mann, J.R., Backlund, M.G., DuBois, R.N., Mechanisms of disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol. 2:4 (2005), 202–210.
77. Nakanishi, Y., Nakatsuji, M., Seno, H., Ishizu, S., Akitake-Kawano, R., Kanda, K., Ueo, T., Komekado, H., Kawada, M., Minami, M., Chiba, T., COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 32:9 (2011), 1333–1339.
78. Quante, M., Varga, J., Wang, T.C., Greten, F.R., The gastrointestinal tumor microenvironment. Gastroenterology 145:1 (2013), 63–78.
79. Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454:7203 (2008), 436–444.